Position
Renaissance Technologies in PharmaCyte Biotech, Inc.
Back to the book · All holders of PMCB
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $3.97K$0.67 → $0.77
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 94K | $68.1K | — | — | — | 0.0% |
| Q1 2026 | 56.5K | $37.6K | $0.67 | −$3.31K | −$27.2K | 0.0% |
| Q2 2026 | 38K | $29.3K | $0.77 | $3.97K | −$12.3K | 0.0% |